Must Reads
Read every Must Reads article with Premium. Try it now with a special intro offer* ยป
Top Biotech Stocks Riding The Rally
Biotech stocks have rebounded after years of underperformance but remain well below their 2021 highs. Successful drug launches, strong trial results, ...
Skip The Bubble And Collect ~14% Dividend With IWMI
The NEOS Russell 2000 High Income ETF (IWMI) offers a compelling alternative to large-cap covered call ETFs heavily concentrated in overvalued SPY and...
Syndax Pharmaceuticals: Thesis Firing On All Cylinders, Sales Acceleration In 2026
Syndax Pharmaceuticals, Inc. remains a Buy, with Revuforj and Niktimvo launches accelerating and a strong clinical and commercial trajectory into 2026...
Meta: Current Selloff A Case Of Post-Metaverse Stress Disorder
Meta Platforms (META) experienced a sharp post-earnings selloff, driven more by investor psychology than company fundamentals, despite strong Q3 reven...
Tesla: Get Out Before The Hype Ends
CEO Elon Musk's compensation plan and political actions pose risks, and even modest performance could reward him excessively without transforming Tesl...
